Navicixizumab (Anti-DLL4)
Navicixizumab (Anti-DLL4) is a bispecific monoclonal antibody targeting DLL4. Navicixizumab can combine with Paclitaxel for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer. MW: 145.5 KD.
| Trivial name | OMP-305B83; Anti-DLL4 Reference Antibody |
| Catalog Number | A2519 |
| CAS# | 1638338-43-8 |
| Size | 1mg*5 |
| Supplier Page | http://www.selleckchem.com/products/navicixizumab-anti-dll4.html |